industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Life Sciences Newsfeed


Tuesday, March 11th, 2014

Webinar Exploring “What’s the Risk? Fearing the Failure in Environmental Monitoring Systems” is Offered for Life Science Companies

AGAWAM, MASS. — March 11, 2014 — A webinar to help life science companies explore the importance of a well-implemented and understood environmental monitoring program, and its ability to generate valuable data, will be offered on Wednesday, March 26, from 1:30 p.m. to 3:30 p.m. EST. The online event will identify the common mistakes and misconceptions regularly encountered when managers “fear the failure” of environmental excursions.

Environmental monitoring systems demonstrate that a company’s various contamination control strategies are operating properly. Such systems can illustrate whether operations are in a state of control. Variations in the data can indicate a drift which could potentially impact product and patient safety.

But the data generated by environmental monitoring system may become skewed when a culture is created which fears environmental failures or excursions. The webinar, What’s the Risk? Fearing the Failure in Environmental Monitoring Systems,” will detail how key life science company management can work to avoid such cultures.

Webinar topics — tailored for quality assurance and control, manufacturing, microbiology, and facilities management in pharmaceutical, biotech, and medical device organizations — will include:

  • The big picture: what systems need to be monitored and why the data is valuable
  • Risk-based environmental monitoring program implementation
  • Culture and “buy-in:” how to create a culture of employee acceptance for contamination control programs
  • Responding to data: how to identify trends in the data and respond with appropriate actions

The webinar will be offered Wednesday, March 26, 1:30 p.m. to 3:30 p.m. EST. Featured speakers include Valerie Montgomery, environmental services manager, and Alison Zulick, environmental services leader, both of Microtest Laboratories, a leading provider of testing services and contract manufacturing for the life science industries.

To register or for more information about the webinar, What’s the Risk? Fearing the Failure in Environmental Monitoring Systems,” visit http://www.microrite.com/training/environmental-monitoring-systems-fearing-the-failure.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and compounding pharmacy industries. Based in Agawam, Massachusetts, USA, Microtest leverages its 30 years industry experience to help its clients meet their regulatory requirements.  For more information, visit http://www.microtestlabs.com or toll-free 1-800-631-1680.

 

# # #

Press contact: Don Goncalves, 1-781-793-9380, dgoncalves@tizinc.com


Tuesday, January 21st, 2014

Brooks Introduces Next-Generation Automated Sample Storage Systems; Feature-Rich, Flexible, Reliable Technology in a Standardized Platform

Brooks SampleStoreTM II system

CHELMSFORD, MASSACHUSETTS, January 21, 2014 — Brooks Life Science Systems, a division of Brooks Automation, Inc. (Nasdaq:BRKS), has introduced its next-generation of automated systems for sample and biological storage. The systems include standardized control software that offers a best-in-class user experience. The company also launched its new “Ask Brooks” expert services portal.

The announcements were made at the Society for Lab Automation and Screening’s 2014 annual conference.

“Our next-generation automated storage systems establish new industry standards for flexibility and reliability,” said Christopher McNary, vice president and chief commercial officer, Brooks Life Science Systems. “We’ve drawn upon the best technologies developed over Brooks’ 15 years of automated storage market leadership to design a storage platform that is highly adaptable to customer needs over the lifetime of the system.”

The flexibility in Brooks’ new sample storage platform comes from its modular architecture and control software. Each system has six bays that can be populated with the industry’s widest range of modules for picking, imaging, and input/output functions. Additional sample banks can be added to the initial system via an internal bridge for future expansion. The control software offers simplified operation and installation. This versatility makes the platform easy to configure and operate, plus highly scalable to meet changing customer requirements.

“We’re leveraging Brooks’ long history in the semiconductor industry where highly reliable products have been a standard requirement for decades,” said McNary. “We incorporate this high level of reliability in our automated storage platforms to improve system uptime for the life science market.”

Built-in Dynamic Storage Optimization technology allocates storage space whenever samples are loaded, eliminating the need to predefine the mix of sample containers. High-density trays increase tube storage up to 65% in the same footprint versus 96-tube racks. A high-throughput configuration can process over 100,000 tube picks per day.

The new standardized sample storage platform consists of the following components:

  • SampleStoreTM II system: for dry powder, small molecule, and DNA samples from room temperature to -20° C with 300,000- to over 10 million-tube storage capacity
  • BioStoreTM II system: for biological sample storage to -80° C with 700,000- to 5 million-tube storage capacity
  • StrataTM automated control software: easy-to-operate and configure icon-based interface with mobile device accessibility. Simple integration with IT/LIMS systems, plus intelligent diagnostics enhances reliability.

“We’ve established a new benchmark for automated sample storage by offering the best user experience, highly flexible configuration, and ultra-reliable operation,” said McNary. “This ensures our customers can meet the changing needs of their applications – from compound storage for drug discovery to DNA, tissue, and blood serum storage for biobanking.”

The company said the first commercial systems are being installed in customer facilities and that orders can be placed immediately with Brooks’ sales representatives.

“Ask Brooks” to Provide Automated Sample Storage Expertise

Brooks also announced it has launched Ask Brooks (http://www.brooks.com/ask-brooks) as part of a new strategic advisory services offering. The Web portal will allow automated sample storage users to question Brooks’ experts about any problems or issues they are facing.

“With over 250 storage systems in place, over 1 billion samples under management, and the industry’s largest engineering staff, we are uniquely qualified to answer tough questions and solve difficult problems,” McNary said. “We encourage sample storage professionals to use the new Web portal when they face challenging applications.”

Users simply type their questions into the form on the Ask Brooks portal and Brooks’ experts will promptly respond.

About Brooks Automation

Brooks is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies, and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, we have been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; we have expanded our reach to meet the needs of customers in the life sciences industry, analytical & research markets, and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe, and Asia. For more information, please visit www.brooks.com.


Tuesday, January 14th, 2014

Fundamentals of Endotoxin Testing for Medical Device Manufacturers are Detailed in New Technical Brief

AGAWAM, MASS. — January 14, 2014 — The fundamentals of endotoxin testing for medical device manufacturers — from definition to assay acceptance criteria —are detailed in new technical brief available from Microtest Laboratories.

Bacterial endotoxins cause fever, septic shock, and other disease symptoms — and thus attract considerable regulatory scrutiny from such organizations as the U.S. Food & Drug Administration (FDA) and the United States Pharmacopeial Convention. Regulations require that devices that contact circulating blood or cerebrospinal fluid, or are used with intraocular products or in vitro fertilization procedures, are required to be endotoxin-free.

The Fundamentals of Endotoxin Testing,” available for download at http://microtestlabs.com/endotoxin-testing, is a step-by-step information resource for medical device manufacturers discussing and detailing the:

  • Definition of endotoxins;
  • Various tests used for their detection;
  • Use of depyrogenation and other ways to remove endotoxins;
  • Types of devices that should be tested;
  • Preparation and testing of samples;
  • Options for sampling containers;
  • Acceptance criteria for each of the assays; and
  • Sources of official information, reference, and guidance.

The Fundamentals of Endotoxin Testing” is authored by Steven Richter, Ph.D., said Steven Richter, Ph.D., president and scientific director of Microtest Laboratories — and a former FDA official.

Download the brief from: http://microtestlabs.com/endotoxin-testing.

The paper is one in a series about testing, manufacturing, and regulatory issues of concern for medical device manufacturers from Microtest Laboratories, a leader in testing services and contract manufacturing for medical devices, pharmaceuticals, and biotechnology.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for medical devices, pharmaceuticals, and biotechnology. It was founded in 1984. The company’s expertise and flexible processes enhance product safety and security, speed time to market, and minimize supply chain disruption. Microtest’s unique single-source capability to provide testing and manufacturing solutions allows the firm to support a full pharmaceutical or medical device product release. The company’s facilities in Agawam, Massachusetts, USA include state-of-the-art aseptic manufacturing areas; analytical chemistry, microbiological, and virological laboratories; Class 100 clean rooms; onsite steam and ethylene oxide sterilization, plus depyrogenation capabilities; purified water systems; and voice/data systems. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs on Facebook at http://goo.gl/TndoBg.

# # #


Tuesday, December 3rd, 2013

Microtest Laboratories Offers OECD Fish Embryo Toxicity Testing

AGAWAM, MASS. — December 3, 2013 — Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries, is adding OECD Fish Embryo Toxicity Testing to its portfolio of services.

Pharmaceutical, chemical, and related manufacturing plants are under increased scrutiny for the potential impact of their products or waste water on the environment. Pesticides are a major example. But recently, the European Commission added three pharmaceutical compounds to its pollutant watch list, citing them as potential risk to the safety of surface water.

“Fish Embryo Toxicity (FET) testing has been developed for environmental and hazard classification applications. The test utilizes the embryo of the Zebrafish and exposes it to various compounds to observe potential toxic effects, thus making FET an ideal method to use in monitoring or investigating environmental cases,” said Steven Richter, Ph.D., president and scientific director of Microtest Laboratories — and former FDA official.

The FET test is an approved OECD (Organization for Economic Co-Operative Development) guideline, published in August, 2013.

““Microtest Laboratories is deeply experienced in fish embryo toxicity testing. We are particularly well-suited to undertake FET testing due to the expertise we’ve developed in creating our Zebrafish Embryo Toxicity (ZET) test, which we’ve been providing as a preliminary screening method in the biocompatibility testing of medical devices and polymers.

“Zebrafish embryos are extensively used in drug development studies due to their transparent embryos and fast development times. The Zebrafish is a well-studied and characterized organism, and ideal as an animal testing model,” Richter noted.

For more information about Microtest Laboratories’ FET testing services, visit http://www.microtestlabs.com/zebrafish-embryos-testing. Or, call 1-413-786-1680 or toll-free at 1-800-631-1680.

In addition, a new whitepaper provides an overview of FET testing. Download “Fish Embryo Toxicology Testing: The Better Alternative for Whole-Effluent Testing” from: http://microtestlabs.com/fish-embryo-toxicology-testing.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free at 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

# # #

Download high-resolution photos for publication from: http://flic.kr/s/aHsjNs2t58


Tuesday, November 19th, 2013

EH&E Named One of The Boston Globe’s Top Places to Work in 2013

Needham, MA — November 19, 2013 –– Environmental Health & Engineering, Inc. (EH&E), a leading provider of environmental and engineering consulting services to the property management, healthcare, research, and biopharma  industries, has been named one of The Boston Globe’s Top Places to Work for 2013.

The Boston Globe’s 2013 Top Places to Work survey recognizes the most progressive companies in Massachusetts, based on employees’ opinions of key factors related to employee happiness including leadership, appreciation, career opportunities, compensation, and management practices in their organizations. This year’s results are based on a survey of 76,000 employees.

“EH&E is an employee-owned company and our people drive the growth and success of our company,” says John McCarthy, President and co-founder of EH&E. “They are passionate about their work and committed to providing customers with exceptional service.  In our 25th year, it is rewarding that their enthusiasm has earned us the distinction of being one of the best places to work in Boston.

EH&E helps businesses and institutions optimize their work environment, environmental compliance programs and building performance to prevent disruptions to vital operations and to maximize alignment with business goals. EH&E has worked with distinguished national organizations and agencies including the US Environmental Protection Agency, Brigham and Women’s Hospital, Massachusetts Institute of Technology, Putnam Investments, Steward Health Care Network, The Broad Institute and Partners Healthcare. Our professional scientific and engineering staff provides expertise in over 80 technical disciplines, and includes internationally recognized experts in many scientific fields. EH&E brings innovative and sound scientific solutions to each business challenge our clients face. EH&E is based in Neeham, Mass. Visit our website at http://www.eheinc.com.


Tuesday, November 12th, 2013

Current Regulatory Expectations Affecting the Validation of Reusable Medical Devices is Subject of Dec. 4th Seminar in Boston

AGAWAM, MASS. — November 12, 2013 — A half-day seminar focusing on current regulatory expectations in the validation of reusable medical devices is the subject of a seminar set for Dec. 4th in Waltham, Mass., near Boston.

The validation of reusable medical devices is at the forefront of the FDA’s efforts to ensure patient safety. Requirements for the cleaning, disinfection, and sterilization of reusable devices are constantly changing. The situation challenges manufacturers both in terms of deciding which testing methods to employ as well as the planning of end points.

The seminar will provide attendees with the knowledge they need to know about current regulatory expectations so they may better prepare their submissions for FDA acceptance — and avoid the time-consuming and costly requirements of additional testing.

Seminar topics will include:

  • Discussion of the FDA’s draft guidance for industry and FDA staff, “Processing/ Preprocessing Medical Devices in Healthcare Settings”
  • Methods used for the cleaning and validation of reusable devices
  • Methods for the disinfection of reusable devices
  • Methods for the sterilization of reusable devices
  • Testing requirements
  • Detailed discussion of endpoints for cleaning validation

The seminar will be presented by Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries, on Wednesday, Dec. 4, 2013, from 9 a.m. to 1 p.m. at the Conference Center at Waltham Woods in Waltham, Mass., just outside Boston. Registration is at 9 a.m. A continental breakfast, break refreshments, and a luncheon are included.

To register, visit http://goo.gl/DvaECn or contact Julie Adamski 1-800-631-1680, ext. 192, or jadamski@microtestlabs.com. Advance registration is $149.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Facebook at http://facebook.com/MicrotestLaboratories, on LinkedIn at http://goo.gl/H8ZLnM or on Twitter @MicrotestLabs.


Tuesday, November 5th, 2013

Outsourcing to a Contract Testing Laboratory is Focus of 2013 AAPS Expo Workshop

AGAWAM, MASS. – Nov. 5, 2013 – The strategies and timing of outsourcing pharmaceutical development processes to a contract testing laboratory will be the focus of a mini-workshop at the 2013 AAPS Annual Meeting and Exposition on Nov. 12, 2013.

“Outsourcing to a contract testing laboratory can save pharmaceutical manufacturers both time and money in drug development and commercialization. But knowing the appropriate time and place to outsource can mean the difference between success and failure,” said Shawn Sherry of Microtest Laboratories.

At the mini-workshop, titled “Outsourcing to a Contract Testing Laboratory, Sherry will overview:

  • The benefits of using turnkey contract laboratory services
  • How to establish a smooth working relationship with your laboratory
  • The importance of the auditing process
  • Quality system, timeline, and pricing factors
  • How Microtest Laboratories can help

The mini-workshop will be presented Nov. 12th from 2:00 p.m. to 2:15 p.m. in the Microtest Laboratories booth, #1325, at the AAPS 2013 Annual Exposition.

Shawn Sherry, Account Development Manager at Microtest Laboratories Inc., has over 11 years’ experience in regulatory microbiology and contract laboratory operations. Sherry holds a BS degree in microbiology and is a nationally registered microbiologist. His experience ranges from compendia testing requirements to aseptic manufacturing, with emphasis on disinfectant qualifications, clean room testing, product testing, and water system validations. He is the co-author of the whitepaper, “Disinfectant Qualifications: Insight and Perspective,” available at http://www.microtestlabs.com/disinfectant-qualifications.

Microtest Laboratories will exhibit in booth #1325 throughout the 2013 AAPS Annual Meeting and Exposition. Microtest Labs is a leader in pharmaceutical contract manufacturing as well as microbiological, analytical, and cleanroom testing services. The company services the pharmaceutical, medical device, and biotechnology industries. Based in Agawam, Mass., Microtest’s testing facilities are ISO 9001 and ISO 17025 certified, FDA regulated, and meet all GLP/GMP standards. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #


Tuesday, October 15th, 2013

Maryland Oncology Hematology Employs Medica’s EasyRA Clinical Chemistry Analyzer to Improve Lab Efficiency, Reduce Cost: Case Study

BEDFORD, Mass. — Oct. 15, 2013 — A case study details how Maryland Oncology Hematology is employing Medica’s EasyRA® Clinical Chemistry Analyzer to increase efficiency and reduce costs at its on-site clinical laboratory — while improving overall patient care.

[Download the case study from the Medica website at http://www.medicacorp.com/resources/easyra-clinical-chemistry-system.]

Maryland Oncology Hematology in Columbia, Md. is a full-service outpatient cancer treatment and testing facility. Visited by 80 to 100 patients a day, the practice provides a variety of cancer treatment therapies including chemotherapy, infusion therapy, injections, and therapeutic phlebotomies. The practice houses a state-accredited clinical laboratory that provides convenient and immediate testing results for patient convenience.

A routine yet essential service performed by many medical centers across the country, including Maryland Oncology Hematology, is the testing of blood samples. Lab technicians work with the patient and their doctor to administer and review blood test results to better guide treatment.

When Maryland Oncology Hematology moved to a new and larger facility, and established a new onsite clinical lab, the practice identified clinical chemistry as work that could be performed in-house. Lab Director Kendra Davies evaluated bench top clinical chemistry analyzers that would meet their four-person lab’s needs and which could be integrated with the lab’s workflow — without requiring additional staffing.

Based on interviews with Davies, the case study reviews how Maryland Oncology Hematology selected and now employs Medica Corporation’s EasyRA chemistry analyzer to realize greater laboratory efficiency and coordination of patient tests, while reducing overall cost. From shorter turnaround time to improved patient care, the case details how the EasyRA chemistry analyzer transformed the way Maryland Oncology Hematology conducted its day-to-day lab Chemistry workload.

Download the case study from the Medica website at http://www.medicacorp.com/resources/easyra-clinical-chemistry-system.

About Medica Corporation

Medica Corporation is a leading provider of easy-to-use, easy-to-maintain, low-cost blood testing analyzers. Based in Bedford, Massachusetts, U.S.A., the company is focused on the global need to reduce the cost and improve the quality of health care. Medica’s products include the EasyLyte®, ISE Module, EasyBloodGas™, EasyElectrolytes™, EasyStat®, EasyRA® and EasyCell® assistant analyzers. For more information, visit http://www.medicacorp.com.

The Medica logo and EasyRA® are registered trademarks of Medica Corporation or its subsidiaries and affiliated companies. All other brands may be trademarks of their respective holders.


Tuesday, October 15th, 2013

Immunetics Introduces Updated BacTx Analyzer for Use with its BacTx Rapid Test for Bacterial Contamination of Platelets

Boston, MA — October 14, 2013 — Immunetics, Inc., a leading clinical test provider, today introduced the updated BacTx® Analyzer for use with its BacTx rapid test for bacteria in whole-blood derived and apheresis platelets. The Analyzer offers automated interpretation, tracking, and documentation — features that not only increase transfusion patient safety, but also provide seamless integration with the laboratory workplace.

The BacTx assay gives hospitals and blood banks a practical tool for assuring the safety of their platelets. The colorimetric assay can detect aerobic, anaerobic, gram-negative and gram-positive bacteria in a single test. The test is designed to enable testing closer to time of transfusion, to reduce the risk of transfusing contaminated platelets.

The updated BacTx Analyzer delivers a faster turnaround of results and a host of new automation and workflow-enhancement features. Complete assay results and analysis are delivered within 30 minutes. STAT, control, and standard assay capabilities allow for testing flexibility. Designed for simple, easy integration, the BacTx Analyzer fits seamlessly into the existing workflow of any laboratory or transfusion center.

“Today, the bacterial contamination of platelets represents a significant risk to the highly vulnerable patients that require transfusions. Existing approaches to detecting bacteria have fallen short, and the industry’s need for an effective, low-cost testing technology is greater than ever,” said John Yonkin, Chief Executive Officer of Immunetics. “Highly sensitive, specific bacterial detection, as provided by the BacTx rapid test with the BacTx Analyzer, helps improve the quality of patient care.”

Features of the updated BacTx Analyzer include:

• Easy and efficient sample preparation;

• Bar code scanning to minimize user input error and maximize efficiency;

• Random access testing that allows multiple assays to be run at different times;

• LED touch screen to simplify operation;

• Logical workflow to accelerate users’ learning curves;

• Passcode and user ID entry that adds security during testing;

• Visual confirmation on both the analyzer and touch screen for best-practice quality control (QC), tracking, and platelet management;

• Automated tracking of tests, trends, and QC;

• USB port for quick and easy download of data

• Small footprint for crowded, cramped lab space.

The BacTx system utilizes a patented, highly specific, universal bacterial detection reagent that has been shown to detect wild and cultured bacterial strains. The assay meets AABB standard 5.1.5.1.1. and can be used for quality-control testing of:

• Leukocyte-reduced apheresis platelets (LRAP) within 24 hours of transfusion, following testing with an FDA-cleared growth-based bacterial detection device.

• Pools of up to six units of leukocyte-reduced whole-blood derived platelets that are pooled within 4 hours of transfusion.

For more information on the BacTx Rapid Assay System, visit the Immunetics Website at http://immunetics.com/bactx.html or contact Immunetics at 1-617-896-9100 or toll-free at 1-800-227-4765.  Immunetics will be displaying the BacTx System at the AABB Annual Meeting and CTTXPO in Booth #527.

About Immunetics

Immunetics, Inc. offers state-of-the-art assay technology for infectious disease diagnosis and blood screening, and for more than 10 years, has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. The company has issued patents on its BacTx test for bacterial contamination of platelets. It has developed and markets other FDA-cleared products, including a test for Lyme disease, and is actively working on new tests for Babesiosis and Chagas disease — both of which are emerging risks to the blood supply. Immunetics is headquartered in Boston, Massachusetts. The company’s mission is to deliver better cost-efficient care through more accurate diagnosis. For more information, visit the Immunetics website at http://immunetics.com.

BacTx® is a registered trademark of Immunetics, Inc.


Wednesday, October 2nd, 2013

“Combination Products: What You Need to Know” Seminar for Medical Device, Pharmaceutical Manufacturers is Scheduled for October 31st in Boston

AGAWAM, MASS. — October 2, 2013 — A full-day technical seminar designed to assist medical device and pharmaceuticals with what they need to know about manufacturing combinations products, including best practices and applicable FDA regulations, is scheduled for Thursday, October 31st, in Waltham, Mass., just outside Boston.

Combination products are a large and growing segment of the medical device market. Some analysts estimate they represent more than 30% of all new FDA product submissions. But for manufacturers, the convergence of drugs, biologics, and devices presents a host of best practice and regulatory issues.

Titled “Combination Products: What You Need to Know,” the seminar will outline a realistic approach for manufacturers to navigate the testing, production, and regulatory standards related to the manufacture of combination products. Topics will include:

  • Combination Products —What You Need To Know: Overview of regulatory hurdles for combination products highlighting the determination of PMOA.
  • Applications of Lean to Combination Product Manufacturing: Case studies specific to applying lean to manufacturing of combo products for clinical use.
  • In-Process and Release Testing PTC: Outline of in-process and release testing points to consider during development and specification determination.
  • EM Monitoring of GMP Manufacturing Space: Current EM procedures for setting up GMP manufacturing.
  • Choosing the Right CMO: Discussion of best practices to determine a right fit CMO.

Combination Products: What You Need to Know,” will be presented by Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. The seminar will be held at the Conference Center at Waltham Woods in Waltham, Mass., just outside Boston, on Thursday, October 31, 2013, from 9:00 a.m. to 3:00 p.m. Registration is at 9:00 a.m. Continental breakfast, break refreshments and luncheon is included.

To register, download the form at http://www.microtestlabs.com. Or, contact Julie Adamski at Microtest Laboratories by phone at 1-800-631-1680, ext. 192, or by email at jadamski@microtestlabs.com. The registration fee is $149.

The seminar is one in a continuing series of technical events presented by Microtest Laboratories for medical device and pharmaceutical manufacturers. The seminars tend to fill up quickly so please register early! Follow Microtest Laboratories on Facebook at http://goo.gl/pHNP63, on LinkedIn at http://goo.gl/H8ZLnM or on Twitter @MicrotestLabs.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.


B2B News is proudly powered by WordPress.
WordPress